Upstream Bio, Inc.
Upstream Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 million, up 20.4% from fiscal 2024. In the quarter to June 2026, revenue fell 17.5%, EPS grew 1.35% and free cash flow grew 9.33%, each against the same quarter a year earlier.
Follow UPB
Upstream Bio, Inc. (UPB) Beneish M-score
Upstream Bio, Inc.'s Beneish M-score for fiscal 2025 is −2.81; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | −2.81 | (9.35) |
| FY2024 | 6.55 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 0.90 | — | 0.83 | |
| Gross margin index | 1.00 | — | 0.53 | |
| Asset quality index | 0.98 | — | 0.39 | |
| Sales growth index | 1.20 | — | 1.07 | |
| Depreciation index Depreciation not reported — index set to 1 | 1.00 | — | Set to 1 | 0.12 |
| SG&A index | 1.28 | — | −0.22 | |
| Total accruals to total assets | (0.03) | — | −0.13 | |
| Leverage index | 1.71 | — | −0.56 | |
| Beneish M-score | Low — no pattern the model associates with manipulation | −2.81 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| TRDA Entrada Therapeutics, Inc. compare | −6.1× |
| STRO Sutro Biopharma, Inc. compare | −3.1× |
| UPB Upstream Bio, Inc. | −2.8× |
| ADCT ADC Therapeutics SA compare | −2.1× |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −1.4× |
| ELDN Eledon Pharmaceuticals, Inc. compare | — |
| ACOG Alpha Cognition Inc. compare | — |
| SION Sionna Therapeutics, Inc. compare | — |
| YARW Yarrow Bioscience, Inc compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI